Crescita Therapeutics Inc
TSX:CTX
Crescita Therapeutics Inc
TSX:CTX
Price:
0.75
CAD
Market Closed
Market Cap:
CA$14m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Crescita Therapeutics Inc
TSX:CTX
|
CA |
|
W
|
WEYCO Group Inc
NASDAQ:WEYS
|
US |
|
Under Armour Inc
NYSE:UAA
|
US |
|
A
|
Aeroporto Guglielmo Marconi di Bologna SpA
F:169
|
IT |
|
Service Corporation International
NYSE:SCI
|
US |
|
Cardno Ltd
ASX:CDD
|
AU |
|
Synergia Energy Ltd
LSE:SYN
|
AU |
|
Riwi Corp
XTSX:RIWI
|
CA |
|
REA Group Ltd
ASX:REA
|
AU |
|
Midland Exploration Inc
XTSX:MD
|
CA |
|
Mercury Metals Ltd
BSE:531357
|
IN |
|
Dno ASA
OSE:DNO
|
NO |
|
Kao Corp
TSE:4452
|
JP |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
US |
|
F
|
First Quantum Minerals Ltd
F:IZ1
|
CA |
|
Cipherpoint Ltd
ASX:CPT
|
AU |
|
R
|
Ras Technology Holdings Ltd
ASX:RTH
|
AU |
|
Anabatic Technologies Tbk PT
IDX:ATIC
|
ID |
Multiples-Based Value
The
Multiples-Based Value for
Crescita Therapeutics Inc (CTX)
under the Base Case is
hidden
CAD.
Compared with the current market price of 0.75 CAD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CTX Multiples-Based Value
LOCKED
Multiples Across Competitors
CTX Competitors Multiples
Crescita Therapeutics Inc Competitors
Crescita Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Crescita Therapeutics Inc
TSX:CTX
|
14m CAD | 0.7 | -151.7 | 11.2 | -5.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 12.6 | 36 | 26.1 | 27.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 5.7 | 26 | 16.7 | 21.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | 11.9 | 13.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 4.7 | 27.4 | 14.9 | 20.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 5 | 20.7 | 13.4 | 17.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 4.2 | 31.1 | 13.7 | 18.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4 | 12.1 | 8.8 | 10.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 2.4 | 19.3 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 407.7 | 4 516.9 | 16.3 | 16.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
